Helixmith Participates in 'BioPlus-InterPhex Korea 2021'

[Asia Economy Reporter Jang Hyowon] Helixmith announced on the 24th that it will participate in the domestic bio conference event, ‘BioPlus-Interphex Korea 2021.’ Helixmith CEO Yoo Seung-shin will present on the CDMO (Contract Development and Manufacturing Organization) business strategy in response to the increased demand for clinical samples of gene and cell therapy products.

‘BioPlus-Interphex Korea’ is a domestic bio event hosted by the Korea Bio Association. Centered around the latest bio industry keywords, key speakers from the industry participate to share research achievements and development technologies. Following last year, this year’s event will also be held online, featuring presentations and partnership meetings to share achievements in gene therapy, gene editing, tissue engineering, and regenerative medicine technologies.

Helixmith has been selected as a major company in the CDMO business and will present on optimized pharmaceutical production strategies. Helixmith entered the CDMO business in line with the explosive increase in domestic and international demand for clinical gene and cell therapy products. In September, it completed the ‘CGT Plant (Cell & Gene Therapy Plant)’ at its headquarters in Magok, Seoul, for the production of gene and cell therapy products.

The CGT Plant is equipped with operational and organizational systems that comply with advanced biopharmaceutical GMP (Good Manufacturing Practice) standards. In particular, it focuses on the smooth supply of high-quality clinical samples through rapid manufacturing and quality analysis of gene and cell therapy-related formulations. It can provide comprehensive solutions across manufacturing, processing, and analysis for gene and cell therapy product production, and notably, it also has a negative pressure manufacturing room for virus vector production.

Helixmith CEO Yoo Seung-shin said, “As a partner to domestic and international gene and cell therapy developers, we hope to provide not only services and solutions but also advance to joint development. We will actively strive to play a valuable role in the development of the gene and cell therapy industry.”